> ## Content Index
> Fetch the complete content index at: https://www.nrdlplus.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# ▶️Making the C-List Work: Lessons and Next Steps for Pharma
- URL: https://www.nrdlplus.com/making-the-c-list-work-lessons-and-next-steps-for-pharma/
- Published: 2025-09-05T11:00:07.000Z
- Updated: 2026-03-03T20:10:12.000Z
- Description: The final Health Policy and Financing Panel wrapped up the C-List Masterclass with reflections, insurer perspectives, global case studies, and Q&A—highlighting how manufacturers can turn C-List inclusion into a true springboard for coverage.
- Author: Kelly Ke
- Tags: Commercial Health Insurance & C-List Dynamics, Coverage & Funding Pathways, C-List Masterclass

[![](https://storage.ghost.io/c/15/10/1510052f-01d9-45db-bfd3-6cc3e958312c/content/images/2025/11/Access360-Subscription-1-1.png)](https://www.nrdlplus.com/archive)

In the closing **Health Policy and Financing Panel** of the C-List Masterclass, we brought together insights from earlier sessions and looked ahead to what the C-List means for pharma strategies in China.

The discussion explored several critical themes:

- **Reflections on prior sessions** and how they connect to the evolving C-List landscape.
- **Commercial insurers’ perspectives**—why their priorities matter for shaping go-to-market strategies and commercial negotiations.
- **Practical next steps for manufacturers** to make C-List inclusion a genuine springboard for coverage, not just a symbolic listing.
- **Two global case studies** offering concrete lessons from outside China that pharma can adapt to shape and strengthen their C-List pathway engagement.
- **Q&A**, where participants raised questions on C-List inclusion priorities, pull-through strategies, and how upcoming reforms may affect multinational vs. local players.

This panel tied the series together with both reflection and forward-looking insights, giving manufacturers pragmatic guidance on how to engage more proactively in China’s emerging multi-level coverage era.

---

[![](https://storage.ghost.io/c/15/10/1510052f-01d9-45db-bfd3-6cc3e958312c/content/images/2025/09/Health-Policy-Financing-panel-thumbnail-w-button.jpg)](https://www.nrdlplus.com/c-list-masterclass-health-policy-and-financing-panel/)

---

### **Panelists:**

**Sejal Mistry**

- Senior Director, Crowell Global Advisors; advises on UHC, health financing, and service innovation in Asia-Pacific
- Led Indonesia’s cervical cancer elimination plan
- Former ACCESS Health SEA head

**Neil Grubert**

- Former VP, Global Market Access Insights, DRG; now independent consultant
- Advised 14 of the top 20 pharma companies worldwide
- Influential LinkedIn voice (25K+ followers); founded *Future of Market Access* LinkedIn community

**Kelly Ke**

- Award-winning former Senior Advisor, Deloitte US Life Sciences Practice
- Founder, bizi LLC, an access intelligence consultancy
- Architect of NRDL+ Executive Debrief, interpreting regulatory signals and implementation dynamics shaping medicine access across China’s multi-layer coverage system

---